Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...

Good morning! Meta's elimination of fact-checking opens the door to misogynistic speech, Jane Fraser faces a test at Citi, ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

The GCC, to be known as the Lilly Capability Centre India (LCCI), will be the company’s second centre in the country, ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...

Though we’re well into the winter season, Lilly Pulitzer always finds a way to get us excited for spring and summer. The ...

The company said that it would be recruiting more than a 1,000 highly-skilled team members to strengthen its digital strategy ...

Eli Lilly establishes new global capability centre in Hyderabad, recruiting over 1,000 skilled team members for digital ...